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Background. Even if is well-established that multimorbidity, the co-existence of two 
or more chronic diseases within the same individual, increases with age and, 
independently of age, it is strongly associated with frailty, disability, hospitalization, 
and mortality, little is known about factors associated with multimorbidity beyond 
age. Epidemiological and clinical studies have found that the “low-grade chronic 
proinflammatory state” tipical of older persons is characterized by high levels of 
serum cytokines and acute phase proteins that are considered risk factors for several 
chronic diseases and predict a variety of adverse health outcomes, including frailty, 
disability, and mortality. Thus, it is reasonable to hypothesize that older persons with 
chronic inflammation are more likely to be affected by or to develop multimorbidity. 
Therefore parsimonious and reliable measures of inflammation may be useful in 
clinical practice as risk assessment tools, as potential therapeutic targets, and to 
monitor clinical progression and effectiveness of interventions. For this reason we 
investigated the relationship between inflammatory biomarkers that can be easily 
measured and adopted by most clinical laboratories with multimorbidity. In particular 
the role of C Reactive Protein (CRP), Cystatin C (Cyst-C) and Lipoprotein (a) (Lp(a)) 
were investigated in the partecipants of the Anziani In Rete (AIR) study. 
 
Methods. In the AIR study a sample was randomly selected by age cohorts (from 65 
to 74, from 75 to 84, and ≥ 85 years) and by gender among all the older subjects 
living in three districts (Brescia Antica, Centro Storico Nord and Centro Storico Sud) 
located in the city center of Brescia, Italy. Each participant was evaluated with a 
comprehensive geriatric assessment and multimorbidity was evaluated as the number 
of chronic diseases within each participant. Information on diseases was derived by a 
physician using different sources of information; self-reported medical history, 
medication use, clinical reports and a medical examination. Population enrolled for 
the study included 134 participants; the mean age was 77.7 (SD 7.6); 59.3% were 
women.  
Demographic and laboratory data of the study population are reported in Table 1.  
 mean median STD deviation 
Age, y 77.7 77 7.65 
Chronic diseases, number 4.12 4 2.3 
Lp(a) 0.26 0.11 0.32 
CRP 4.69 3 7.21 
Cyst-C 1.18 1.07 0.47 
 
Table 1. Demographic and laboratory data of the study population 
 
Venous blood samples were obtained and commercially available assays were used 
according to manufacturer’s instruction: serum Lp(a) was measured with the latex 
lipoprotein reagent, and Cyst-C and CRP plasma levels were measured using 
immunoassay techniques (reagents from Siemens Healthcare Diagnostics, Den 
Hague, The Netherlands), all determinations were carried out in Dimension® Vista™ 
1500 analyzer (Siemens Diagnostics). For the purpose of the present study, we used 
the biomarkers levels both as linear variables and categorized according to the 
references values suggested by the literature and by manufacturer’s instruction and 
adopted by clinicians; in particular we considered as high values levels of Lp(a) > 0,3 
g/L,  Cyst-C value > 1.11 mg/L and CRP > 5 mg/L. 
Sociodemographic and laboratory data according to being affected by 0/1, 2-3 or 4+ 
chronic diseases are showed in Table 2. 
Disease (number) 
0/1  2/3  more than 4  P-value 
Age, mean(SD) 73(1.2) 77.3(0.94) 78.9(0.73) 0.0005 
female sex, % 45.8 52.4 66.1 0.023 
education, 
median(IQR) 13(13-18) 13(8-18) 13(8-13) 0.007 
 
    
CRP <5mg/L, % 92.9 82.2 65.3 0.03 
Lp(a) <0.3g/l,% 85.7 86.4 60.3 0.005 
Cyst C < 1.11 mg/L,% 91.7 61.5 43.1 0.004 
 
Table 2: Sociodemographic and laboratory according to number of pathologies. 
 
Increasing age, female sex and lower education were significantly associated with 
higher number of diseases. The majority of  persons in the group of those with zero or 
1 disease had normal levels of the markers but as the number of chronic diseases 
increased the percentage of person with normal value of the markers decreased.  
Two multivariate linear regression models were run to test the association between 
the three biomarkers and multimorbidity (number of diseases). The first model was 
run including CRP, Lp(a) and Cyst-C categorized according to previously defined 
cut-off points. Higher levels of all the three markers were associated with higher 
number of diseases after adjusting for age and sex (Table 3). 
 
Number of chronic disease Coef. P>z [95% Conf.Interval] 
Cyst C 0.926 0.044 0.025 1.828 
Lp(a) 1.529 0.001 0.625 2.432 
CRP 0.961 0.038 0.052 1.870 
Sex -0.726 0.071 -1.514 0.063 
Age -0.002 0.945 -0.062 0.058 
 
Table 3. Linear regression model testing the association between laboratory data 
(categorized) and number of chronic diseases 
The second model was run including CRP, Lp(a) and Cyst-C as continuous variables. 
Results from this model showed that Lp(a) and Cyst-C, but not CRP were still 
significantly associated with increasing number of diseases (Table 4).  
 
Number of chronic disease Coef. P>z  [95% Conf.Interval] 
Cyst C 1.467 0.021 0.220 2.714 
Lp(a) 1.771 0.005 0.522 3.020 
CRP 0.002 0.930 -0.052 0.057 
Sex -0.906 0.033 -1.737 -0.074 
Age 0.003 0.927 -0.062 0.068 
 
Table 4. Linear regression model testing the association between laboratory data 
(continuous) and number of chronic diseases 
 
Conclusion. The main findings of this study show that CRP, Lp(a) and Cyst-C levels 
increase with increasing number of chronic diseases in older persons. Similarly, the 
percentage of older persons with normal values of the three markers decrease with 
multimorbidity. Our findings extend the results of previous studies on the 
associations between inflammation and multimorbidity in older people by 
demonstrating a clear association with CRP, Lp(a) and Cyst-C. Differently from the 
most studied markers of inflammation, we propose the use of diagnostic assay 
already available in most of clinical laboratories. Standardized protocols, well 
defined range limits, quality internal and external controls and low costs compared to 
research assay make them more interesting for monitoring inflammation and related 
health conditions in older person. 
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